MA62939A1 - Composition pharmaceutique de pembrolizumab et son utilisation - Google Patents

Composition pharmaceutique de pembrolizumab et son utilisation

Info

Publication number
MA62939A1
MA62939A1 MA62939A MA62939A MA62939A1 MA 62939 A1 MA62939 A1 MA 62939A1 MA 62939 A MA62939 A MA 62939A MA 62939 A MA62939 A MA 62939A MA 62939 A1 MA62939 A1 MA 62939A1
Authority
MA
Morocco
Prior art keywords
pembrolizumab
compositions
pharmaceutical composition
treatment
infectious diseases
Prior art date
Application number
MA62939A
Other languages
English (en)
Inventor
Ekaterina Aleksandrovna Lomkova
Dmitry Valentinovich Morozov
Aleksandr Olegovich Iakovlev
Alina Aleksandrovna Kostandian
Anastasiia Alekseevna Andreeva
Original Assignee
Biocad Joint Stock Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from RU2021112111A external-priority patent/RU2791857C2/ru
Application filed by Biocad Joint Stock Co filed Critical Biocad Joint Stock Co
Publication of MA62939A1 publication Critical patent/MA62939A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne le domaine de la pharmacie et de la médecine, en particulier des compositions pharmaceutiques de pembrolizumab à base d'anticorps anti-pd-1, qui peuvent être des compositions aqueuses ou lyophilisées. L'invention concerne en outre l'utilisation desdites compositions pour le traitement de néoplasmes malins ou de maladies infectieuses, ainsi que l'utilisation desdites compositions pour fabriquer un produit médicinal destiné au traitement de néoplasmes malins ou de maladies infectieuses.
MA62939A 2021-04-27 2022-04-27 Composition pharmaceutique de pembrolizumab et son utilisation MA62939A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
RU2021112111A RU2791857C2 (ru) 2021-04-27 Фармацевтическая композиция пембролизумаба и ее применение
PCT/RU2022/050140 WO2022231481A1 (fr) 2021-04-27 2022-04-27 Composition pharmaceutique de pembrolizumab et son utilisation

Publications (1)

Publication Number Publication Date
MA62939A1 true MA62939A1 (fr) 2024-02-29

Family

ID=83848424

Family Applications (1)

Application Number Title Priority Date Filing Date
MA62939A MA62939A1 (fr) 2021-04-27 2022-04-27 Composition pharmaceutique de pembrolizumab et son utilisation

Country Status (14)

Country Link
EP (1) EP4329729A4 (fr)
CN (1) CN117835965A (fr)
AR (1) AR125470A1 (fr)
CL (1) CL2023003209A1 (fr)
CO (1) CO2023014166A2 (fr)
CR (1) CR20230527A (fr)
EC (1) ECSP23081880A (fr)
JO (1) JOP20230267A1 (fr)
MA (1) MA62939A1 (fr)
MX (1) MX2023012745A (fr)
PE (1) PE20250072A1 (fr)
PY (1) PY2231960A (fr)
TW (1) TW202308692A (fr)
WO (1) WO2022231481A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024171082A1 (fr) * 2023-02-16 2024-08-22 Sun Pharmaceutical Industries Limited Compositions de protéines stables d'anticorps anti-pd1

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20201334T1 (hr) * 2015-04-17 2020-11-27 Bristol-Myers Squibb Company Kompozicije koje sadrže kombinaciju ipilimumaba i nivolumaba
US11608357B2 (en) * 2018-08-28 2023-03-21 Arecor Limited Stabilized antibody protein solutions
JOP20190260A1 (ar) * 2017-05-02 2019-10-31 Merck Sharp & Dohme صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
US10646569B2 (en) * 2017-05-16 2020-05-12 Bhami's Research Laboratory, Pvt. Ltd. High concentration protein formulations with reduced viscosity
US20210380694A1 (en) * 2018-11-07 2021-12-09 Merck Sharp & Dohme Corp. Stable formulations of programmed death receptor 1 (pd-1) antibodies and methods of use thereof

Also Published As

Publication number Publication date
PY2231960A (es) 2022-11-25
AR125470A1 (es) 2023-07-19
EP4329729A1 (fr) 2024-03-06
PE20250072A1 (es) 2025-01-13
JOP20230267A1 (ar) 2023-10-26
TW202308692A (zh) 2023-03-01
CL2023003209A1 (es) 2024-05-31
MX2023012745A (es) 2023-11-09
ECSP23081880A (es) 2023-11-30
EP4329729A4 (fr) 2025-04-02
WO2022231481A1 (fr) 2022-11-03
CR20230527A (es) 2024-02-13
CN117835965A (zh) 2024-04-05
CO2023014166A2 (es) 2024-02-05

Similar Documents

Publication Publication Date Title
MA54663A1 (fr) Composition pharmaceutique aqueuse d'un anticorps anti-il17a et son utilisation
MA46665B1 (fr) Composés de tyrosine tyrosine de peptide cyclique couplés à un anticorps en tant que modulateurs des récepteurs du neuropeptide y
MA41558B1 (fr) Compositions d'allergènes mélangés et leurs procédés d'utilisation
MA47392A1 (fr) Bis-octahydrophénanthrène carboxamides et leurs conjugués protéiques
MA27710A1 (fr) Formulations pharmaceutiques liquides de palonosetrone
MA35800B1 (fr) Compositions pharmaceutiques comprenant des anticorps humains contre pcsk9
EP1649849A3 (fr) Compositions pour le traitement de la maladie de parkinson contentant un antagoniste du récepteur CB1 et un produit qui active la neurotransmission dompaminerque dans le cerveau
MA34120B1 (fr) Composition pharmaceutique
MA38576B2 (fr) Formulations de colchicine à libération prolongée et procédés d'utilisation de ces dernières
MA63861A1 (fr) Composition pharmaceutique de virus non enveloppé
MA67288A1 (fr) Tubulysines et conjugués tubulysines-protéines
MA30413B1 (fr) Nouvelles compositions pharmaceutiques faiblement dosees contenant du nimesulide, leur preparation et utilisation
MA45972B1 (fr) Unité posologique orodispersible contenant un composant d'estétrol
EP4174091A4 (fr) Anticorps monocaténaire anti-cd44 et son utilisation dans la préparation d'un médicament pour le traitement d'une tumeur
MA37742A1 (fr) Dérivés d'oestra-1,3,5 (10), 16-tétraène substitués en position 3, leurs procédés de préparation, préparations pharmaceutiques les contenant, et leur utilisation pour la fabrication de médicaments
MA37317B1 (fr) Formulation d'anticorps il-17
FR3058059B1 (fr) Composition pharmaceutique comprenant le beta-elemene, le lupeol et le 2-hydroxycinnamaldehyde et/ou le 2'-benzoyloxycinnalmaldehyde et/ou le beta-sitosterol et/ou la curcumine.
MA50201B1 (fr) Comprimés de défériprone à libération retardée et procédés d'utilisation correspondants
MA38688A1 (fr) Composition solide pour administration orale contenant de l'acide ibandronique ou un sel pharmaceutiquement acceptable de celui-ci et de la vitamine d
MA30035B1 (fr) Utilisation d'un extrait insaponifiable de pulpe vegetale dans le traitement du vieillssement cutane
FR3104908B1 (fr) Solubles de pois fermentes
EP3677272A4 (fr) Application de alistipes shahii dans la préparation d'une composition pour la prévention et/ou le traitement de maladies associées au métabolisme lipidique
FR3059236B1 (fr) Extraits de plantes du genre tagetes et leurs utilisations
MA70850A1 (fr) Composition pharmaceutique d'anticorps anti-cd20 et son utilisation
MA58507A1 (fr) Composition pharmaceutique aqueuse de levilimab